- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Swedish Orphan Biovitrum publ (0MTD)Assess today's live Swedish Orphan Biovitrum AB (SOBIV) share price, performance and insights using our live Stockholm: SOBIV stock exchange data.
Analyse the historical data and Swedish Orphan Biovitrum AB share price performance charts on this page. Our technical summary section provides analysis on Swedish Orphan Biovitrum share price buy/sell indicators using real-time data (or discuss the Swedish Orphan Biovitrum (SOBIV) stock price today with other investors in the Swedish Orphan Biovitrum ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST SOBIV share price (ISIN: SE0000872095) to enhance your trading decisions with our free investment tools and resources.
What Is the Swedish Orphan Biovitrum AB Share Price Today?
The Swedish Orphan Biovitrum share price today is 314.70.
What Is the Stock Symbol for Swedish Orphan Biovitrum AB
The stock symbol (or 'ticker') for Swedish Orphan Biovitrum AB is "SOBIV."
What Stock Exchange Does Swedish Orphan Biovitrum AB Trade On?
Swedish Orphan Biovitrum AB is listed and trades on the Stockholm stock exchange.
Is Swedish Orphan Biovitrum AB a Good Stock to Buy?
Determining whether Swedish Orphan Biovitrum AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Swedish Orphan Biovitrum AB share price performance charts on this page. Our technical summary section provides analysis on Swedish Orphan Biovitrum share price buy/sell indicators using real-time data (or discuss the Swedish Orphan Biovitrum (SOBIV) stock price today with other investors in the Swedish Orphan Biovitrum ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST SOBIV share price (ISIN: SE0000872095) to enhance your trading decisions with our free investment tools and resources.
What Is the Swedish Orphan Biovitrum AB Share Price Today?
The Swedish Orphan Biovitrum share price today is 314.70.
What Is the Stock Symbol for Swedish Orphan Biovitrum AB
The stock symbol (or 'ticker') for Swedish Orphan Biovitrum AB is "SOBIV."
What Stock Exchange Does Swedish Orphan Biovitrum AB Trade On?
Swedish Orphan Biovitrum AB is listed and trades on the Stockholm stock exchange.
Is Swedish Orphan Biovitrum AB a Good Stock to Buy?
Determining whether Swedish Orphan Biovitrum AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
314.70
-2.10(-0.66%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
314.70
317.60
52 wk Range
243.20
354.60
0MTD Scorecard
Full Analysis
3 analysts have revised their earnings downwards for the upcoming period
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
314.70317.60
52 wk Range
243.20354.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
0MTD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
359.73
Upside
+14.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Swedish Orphan Biovitrum AB Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
Compare 0MTD to Peers and Sector
Metrics to compare | 0MTD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0MTDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.0x | −1.4x | −0.6x | |
PEG Ratio | 2.33 | −0.02 | 0.00 | |
Price/Book | 2.9x | 2.3x | 2.6x | |
Price / LTM Sales | 4.3x | 6.2x | 3.2x | |
Upside (Analyst Target) | - | 113.5% | 49.4% | |
Fair Value Upside | Unlock | 27.9% | 7.8% | Unlock |
People Also Watch
FAQ
What Is the Swedish Orphan Biovitrum (0MTD) Stock Price Today?
The Swedish Orphan Biovitrum stock price today is 314.70
What Stock Exchange Does Swedish Orphan Biovitrum Trade On?
Swedish Orphan Biovitrum is listed and trades on the London stock exchange.
What Is the Stock Symbol for Swedish Orphan Biovitrum?
The stock symbol for Swedish Orphan Biovitrum is "0MTD."
What Is the Swedish Orphan Biovitrum Market Cap?
As of today, Swedish Orphan Biovitrum market cap is 108.25B.
What is Swedish Orphan Biovitrum Earnings Per Share?
The Swedish Orphan Biovitrum EPS is 10.21.
What Is the Next Swedish Orphan Biovitrum Earnings Date?
Swedish Orphan Biovitrum will release its next earnings report on 05 Feb 2025.
From a Technical Analysis Perspective, Is 0MTD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.